<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873999</url>
  </required_header>
  <id_info>
    <org_study_id>PV500ped</org_study_id>
    <nct_id>NCT04873999</nct_id>
  </id_info>
  <brief_title>Prospective, Open, Non-interventional Study to Assess the Ability of an Electrical Impedance Tomograph (PlumoVista 500)</brief_title>
  <acronym>PV500ped</acronym>
  <official_title>Prospective, Open, Non-interventional Study to Assess the Ability of an Electrical Impedance Tomograph (PlumoVista 500) to Monitor Changes in Lung Ventilation Over Time in Mechanically Ventilated Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drägerwerk AG &amp; Co. KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drägerwerk AG &amp; Co. KGaA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational PMCF study will be conducted to generate and gather clinical data from the&#xD;
      intended target population of pediatric patients.&#xD;
&#xD;
      The intention for Post-Market Clinical Follow-up (PMCF) is to confirm the performance and&#xD;
      safety of a device throughout the device's lifecycle.&#xD;
&#xD;
      PulmoVista 500 is a lung function monitor for clinical use which continuously generates&#xD;
      cross-sectional images of the lung function by applying the technique of electrical impedance&#xD;
      tomography (EIT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>assess the capability of PulmoVista 500 for continuous monitoring of ventilation</measure>
    <time_frame>Duration per participant: 2 - 3 days (screening, procedure with PulmoVista 500, safety follow-up). Measurements with PulmoVista 500 per patient during mechanical ventilation is anticipated for a maximum of 10 minutes in total.</time_frame>
    <description>To assess the capability of PulmoVista 500 for continuous monitoring of ventilation, the cross-correlation function (CCF) between the global impedance waveform of EIT and global tidal volume waveforms of a ventilator across multiple respiratory cycles in patients under controlled mechanical ventilation, will be evaluated.</description>
  </primary_outcome>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Monitoring of Regional Distribution of Ventilation</condition>
  <condition>Monitoring of Lung Volume</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients that visit the hospital for any kind of surgery, therefore requireing&#xD;
        mechanical ventilation. Monitoring of Regional Distribution of Ventilation and Lung Volume&#xD;
        are of clinical interest in these patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pediatric male or female patients excluding preterm infants&#xD;
&#xD;
          2. Patients with a chest circumference between 36 and 72 cm&#xD;
&#xD;
          3. Patients ≤ 12 years.&#xD;
&#xD;
          4. Patients with a tidal volume &gt; 20 ml, i.e., children with a body weight of more than&#xD;
             3.3 kg (assuming a targeted tidal volume of 6 mL/kg body weight)&#xD;
&#xD;
          5. Patients for whom mechanical ventilation is intended&#xD;
&#xD;
          6. Patients whose regional distribution of ventilation and of lung volume are of clinical&#xD;
             interest&#xD;
&#xD;
          7. Patients who are (should be) ventilated via an artificial airway access, whereby the&#xD;
             ventilator used is compatible with PulmoVista 500&#xD;
&#xD;
          8. Patients and / or their legal guardians or legal representatives who have given&#xD;
             written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are supplied with a permanent or temporary pacemaker, an implantable&#xD;
             defibrillator or other medical devices that emit electrical energy (e.g. cochlea&#xD;
             amplifier implant)&#xD;
&#xD;
          2. Patients with a tidal volume ≤ 20 ml&#xD;
&#xD;
          3. Patients in whom the application of the electrode belt could be impaired by wound care&#xD;
             or infections in the chest area&#xD;
&#xD;
          4. Female patients for whom pregnancy cannot be excluded; a pregnancy test should be&#xD;
             performed at the discretion of the investigator.&#xD;
&#xD;
          5. Patients with an alleged allergic reaction to the materials of the electrode belt&#xD;
&#xD;
          6. Patients with a Body Mass Index (BMI) &gt; 40&#xD;
&#xD;
          7. Evidence that suggests that the patient or their legal representative will not comply&#xD;
             with the protocol requirements&#xD;
&#xD;
          8. Patients with a proven infectious disease (e.g. SARS-COV-19, MRSA) that requires&#xD;
             isolation of the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Wolf, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's hospital Traunstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

